Oryzon Genomics Granted U.S. Patent for Iadademstat Combinations with Venetoclax

Key combination for the treatment of first-line acute myeloid leukemia (AML)

Mar. 23, 2026 at 6:40am

Got story updates? Submit your updates here. ›

Oryzon Genomics, a clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent covering therapeutic combinations of iadademstat, Oryzon's LSD1 inhibitor, with venetoclax, a backbone therapy in the current standard of care for first-line acute myeloid leukemia (AML). The patent is expected to expire in January 2039 and strengthens the long-term value of Oryzon's clinical programs.

Why it matters

This patent grant represents a significant addition to Oryzon's intellectual property portfolio for iadademstat, which is currently being evaluated in several ongoing oncology clinical trials, including a Phase Ib study in first-line AML in combination with venetoclax and azacitidine that has shown a 100% overall response rate and 90% strict complete remission rate.

The details

The granted U.S. patent includes claims covering methods of treating neoplastic diseases, including AML, using combinations of iadademstat and other therapeutic agents, notably venetoclax. In addition to this U.S. patent, Oryzon has obtained patent protection for iadademstat combinations with venetoclax in several other countries, and the company also holds granted patents covering combinations of iadademstat with other AML therapies, including azacitidine and decitabine.

  • The U.S. patent is expected to expire in January 2039, including 681 days of patent term adjustment granted by the USPTO.
  • Oryzon presented highly encouraging preliminary data from the Phase Ib ALICE-2 study in first-line AML at the American Society of Hematology (ASH) 2025 Annual Meeting.

The players

Oryzon Genomics, S.A.

A clinical-stage biopharmaceutical company and global leader in epigenetics, headquartered in Barcelona, Spain, with an advanced clinical portfolio built around two LSD1 inhibitors, iadademstat and vafidemstat.

Iadademstat

Oryzon's potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, including ongoing trials in acute myeloid leukemia (AML).

Venetoclax

A backbone therapy in the current standard of care for first-line acute myeloid leukemia (AML).

Got photos? Submit your photos here. ›

What they’re saying

“This U.S. patent grant represents a significant addition to our growing IP portfolio for iadademstat. This patent covers combinations with venetoclax, the current standard of care in first-line AML, and provides protection extending into 2039, strengthening the long-term value of our clinical programs.”

— Neus Virgili, Chief IP Officer, Oryzon Genomics

What’s next

Updated data from approximately 15-16 patients (around 75% of the planned enrollment) in the Phase Ib ALICE-2 study evaluating iadademstat in combination with venetoclax and azacitidine in first-line AML are expected to be presented at the European Hematology Association Annual Congress (EHA) in June 2026.

The takeaway

This patent grant highlights the strategic importance of iadademstat's combination with venetoclax, the current standard of care in first-line AML, and demonstrates Oryzon's commitment to building a robust intellectual property portfolio to support the long-term development and commercialization of its lead oncology program.